Insider Trading Review: Verastem, Inc. $VSTM

beed18bc04ae29af3c7904e660295dcc

Verastem, Inc. (VSTM) insider have most recently took part in a trading activity. On Dec 5, 2017 Barberich Timothy J, Director bought 60,538 shares having total worth of $239,125 at the price of $3.95 per share, following the transaction a total of 130,000 shares owned by Barberich Timothy J. Before this latest buy, Barberich Timothy J purchased VSTM at 1 other times during the past twelve months, for a total investment of $73,500 at an average of $2.45 per share.

Furthermore, over the past 12 months , the stock was traded 1 times by insiders. an employee of the company was the buyer in 1 instances.

Shares of Verastem, Inc. (VSTM) traded down 2.31% on Dec 6, 2017, hitting $3.81. 440,116 shares of the company’s stock traded hands. Verastem, Inc. has a 52 week low of $1.07 and a 52 week high of $5.41. The company’s market cap is $51 million.

Verastem, Inc. (VSTM) last announced its earnings results on Nov 7, 2017. The company reported -0.61 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.32 by $0.29. During the same quarter in the previous year, the company posted -0.21 earnings per share.

2017-11-07 2017-08-08 2017-05-10 2017-03-23 2016-08-08 2016-03-03 2015-11-09 2015-08-10 2015-05-11 2015-01-08
earnings per share -0.61 -0.36 -0.35 -0.32 -0.23 -0.32 -0.42 -0.42 -0.46 -0.53
Revenue(M) 0 0 0 0 0 0 0 0 0 0

Verastem Inc was incorporated under the laws of the State of Delaware in August 2010. The company is a biopharmaceutical company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells in breast and other cancers along with proprietary companion diagnostics. It licenses its EMT technology from the Whitehead Institute for Biomedical Research, an affiliate of the Massachusetts Institute of Technology, or MIT, and the President and Fellows of Harvard College, or Harvard. Its advanced product candidates are VS-507, VS-4718 and VS-5095. The company is currently evaluating these compounds in preclinical studies as potential therapies for breast and other cancers. Its products include VS-507 – The Company is currently evaluating VS-507 in preclinical studies as a potential therapy for breast cancer. Its scientific co-founders identified VS-507 using the proprietary technology that it license from the Whitehead Institute and published the results in the peer reviewed scientific journal Cell in 2009. The company holds an exclusive license from the Whitehead Institute for use of VS-507 in treating cancer. The company expects to initiate a clinical trial with VS-507 over the next 12 to 15 months. It is currently evaluating VS-4718 and VS-5095 as potential therapies for cancers with a percentage of CSCs. The company identified the CSC-targeted activity of these compounds using its proprietary technology and hold worldwide exclusive rights to these compounds and their use. It expect to initiate a clinical trial with one of either VS-4718 or VS-5095 over the next 12 to 15 months. It believe VS-4718 and VS-5095 target CSCs through inhibition of FAK signaling. FAK expression is greater in many tumor types compared to normal tissue, particularly in cancers that have an invasive and metastatic capability. The contact between epithelial cancer cells and connective tissue stimulates FAK signaling. However, epithelial cancer cells that undergo EMT acquire the ability to survive in the absence of contact with connective tissue. The company thinks that FAK signaling in CSCs may be maintained through alternative mechanisms, thus providing CSCs the ability to survive in the absence of cell contact. Accordingly, it thinks that FAK signaling may be a central component of CSC biology that allows CSCs to survive after exiting from a tumor mass and enable metastasis to other sites in the body. It has initiated NCE programs on more than 10 series of chemical compounds identified using its proprietary EMT technology along with throughput screening methods. In addition, it has synthesized several drug candidates that are chemically similar to VS-507 and are currently optimizing their activity to block Wnt/beta-catenin signaling and induce selective killing of CSCs. The company faces competition from other pharmaceutical companies including Astellas Pharma Inc., Sanofi-Aventis U.S. LLC, GlaxoSmithKline plc, Boehringer In

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.